Generate Biomedicines Inc (GENB)

Generate Biomedicines, Inc. is a biotechnology company focused on generative biology and the use of machine learning to support drug discovery and development. The company develops novel protein therapeutics through protein-based modalities and is advancing a pipeline that includes GB-0895, an investigational long-acting anti-TSLP monoclonal antibody for severe asthma designed for dosing every six months, GB-4362, an MMAE payload neutralizer monoclonal antibody, and GB-5267, a MUC16 CAR-T cell therapy. It is also developing the Generate Platform, a therapeutic-area and protein-modality agnostic system that combines computational methods with scalable biohardware to address challenges beyond traditional technologies. Formerly known as Generate Biologics, Inc., the company adopted its current name in February 2020 and was incorporated in 2018. Generate Biomedicines is based in Somerville, Massachusetts, and its common stock trades on NASDAQ under the symbol GENB.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.